Although GLP-1 RAs are not yet first-line therapies for nephropathy, current the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend them in patients with T2DM and CKD when SGLT2 inhibitors are contraindicated or insufficient [9,10]. This evidence concerns the gene SLC5A2 and kidney disorder.